Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17112853 | 0.92 | ESR2 (0.40) | ESR2ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL22263473 | 0.87 | ALDH1A1 (0.39) | ESR2ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19722236 | 0.86 | ESR2 (0.48) | ESR2ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1188054 | 0.82 | KMT2A (0.37) | ALDH1A1KMT2APOLBSMN1; SMN2SPR | |
| SCHEMBL24791077 | 0.81 | ESR2 (0.47) | ESR2ALDH1A1HPGDMAPK1HSD17B10 | |
| SCHEMBL15798242 | 0.80 | ESR2 (0.49) | ESR2ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2502784 | 0.79 | — | — | |
| SCHEMBL16321630 | 0.79 | ESR2 (0.48) | ESR2ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1563963 | 0.78 | ESR2 (0.50) | ESR2ALDH1A1CYP3A4CYP2C19HPGD | |
| SCHEMBL10000017 | 0.78 | ALDH1A1 (0.31) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092071-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | UNIV MICHIGAN (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20240368181-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| EP-3753926-B1 | SPIRO COMPOUND AS INDOLEAMINE-2,3-DIOXYGENASE INHIBITOR | SHANGHAI INST ORGANIC CHEMISTRY CAS (CN) | 2024-10-09 | — | — | EP | disclosed |
| EP-4402276-A1 | PROCESS TO PRODUCE (1 R, 4 R)-4-SUBSTITUTED CYCLOHEXANE-1-AMINES | Richter Gedeon Nyrt. (HU) | 2024-07-24 | — | — | EP | disclosed |
| WO-2024064328-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-03-28 | — | — | WO | disclosed |
| US-11932601-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| EP-4288426-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | Black Diamond Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023220640-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20010007870-A1 | Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives administered as antitumor agents | REMISZEWSKI STACY W (US) | 2001-07-12 | — | — | US | disclosed |
| US-6211193-B1 | BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDINE DERIVATIVES; ANTITUMOR AND ANTICARCINOGENIC AGENTS | SCHERING CORPORATION | 2001-04-03 | — | — | US | disclosed |
| CN-1286690-A | Compounds useful for inhibition of farnesyl protein transferase | SCHERING CORP (US) | 2001-03-07 | — | — | CN | disclosed |
| EP-0993459-A1 | COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 2000-04-19 | — | — | EP | disclosed |
| US-5877199-A | ALZHEIMER'S DISEASE; SEDATIVE | SANKYO COMPANY, LIMITED (JP) | 1999-03-02 | — | — | US | disclosed |
| WO-1998057955-A1 | COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
| EP-0804416-A1 | HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS | SANKYO COMPANY LIMITED (JP) | 1997-11-05 | — | — | EP | disclosed |
| EP-0802897-A1 | NOVEL COMPOUNDS | Smithkline Beecham S.p.A. (IT) | 1997-10-29 | — | — | EP | disclosed |
| WO-1996021638-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM S.P.A. (IT) | 1996-07-18 | — | — | WO | disclosed |
| WO-1996003377-A1 | HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS | SANKYO COMPANY, LIMITED (JP) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007870-A1 | Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives administered as antitumor agents | HCCS, FNTB, CBR1 | ESR2 2997/4885ALDH1A1 795/4885CYP3A4 883/4885 |
| US-11932601-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | ESR2 1493/4885ALDH1A1 219/4885CYP3A4 1482/4885 |
| US-20240368181-A1 | QUINOXALINE DERIVATIVES AND USES THEREOF | NQO2, NQO1, GLS | ESR2 3354/4885ALDH1A1 701/4885CYP3A4 98/4885 |
| US-20260092071-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | SMARCC2, SMARCC1, SMARCA2 | ESR2 99/4885ALDH1A1 1136/4885CYP3A4 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.